Atlas Trials

CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas

Clinical trial NCT02766270 · UNKNOWN

Trial details

NCT number
NCT02766270
Sponsor
Beijing Tiantan Hospital
Status
UNKNOWN
Phase
Early Phase 1
Study type
INTERVENTIONAL
Grade II/III Glioma
Start date
2016-09-26
Primary completion
2017-12-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.